prostate cancer

[Cell Reports Medicine] The authors demonstrated that SU086 inhibited the growth of prostate cancer cells in vitro, cell-line and patient-derived xenografts in vivo, and ex vivo prostate cancer patient specimens.

[Cell Chemical Biology] Investigators performed functional and synthetic lethal screens in four prostate cancer cell lines which confirmed key roles for HSP70, HSP90, and their co-chaperones, and suggested that the mitochondrial chaperone, HSP60/HSPD1, was selectively required in CRPC cell lines.

[Molecular Therapy] Researchers demonstrated that retinoblastoma (Rb) family proteins played a central role in maintaining the global chromatin binding and transcriptional repression program of androgen receptor, and that Rb inactivation desensitized CRPC to the high-dose testosterone treatment in vitro and in vivo.

[Proceedings of the National Academy of Sciences of the United States of America] The authors identified the up-regulation of prostate-specific membrane antigen (PSMA)-like aminopeptidase NAALADaseL and the metabotropic glutamate receptors in PSMA-suppressed prostate cancers.

[Cancer Science] Scientists investigated the effect of PMD-026 on YB-1/AR signaling and its antitumor effect in prostate cancer in vitro and in vivo and demonstrated an excellent antitumor effect of the novel ribosomal S6 kinase inhibitor PMD-026 and the combination effect with the antiandrogen enzalutamide in CRPC.

[Clinical and Experimental Pharmacology and Physiology] The authors explored the effect of the upregulation or downregulation of the NPM1 protein on the malignancy of prostate cancer and its possible signaling pathway.